ASCI Honors Two Scientists Who Rewired Prostate Cancer Biology
The 2026 ASCI/Harrington Prize for Innovation in Medicine went to Arul M. Chinnaiyan, MD, PhD, and Charles L. Sawyers, MD, for discoveries that changed how prostate cancer is understood, diagnosed, and treated. Their careers track two different scientific routes into the same problem: how to identify the molecular engines of cancer and then turn that knowledge into therapy. In the interview that accompanied the award, both physicians described careers shaped less by linear planning than by persistent attention to biology, resistance, and the clues hidden in patient samples.
Their recognition reflects more than personal achievement. It marks the maturation of a field in which gene fusions, kinase signaling, and resistance mechanisms moved from laboratory curiosities to clinical decision points.
From CML to Hormone Resistance and the Logic of Drug Escape
Sawyers traced his scientific formation to leukemia, where chromosomal translocations offered a direct route to defining a driver lesion. The appeal of chronic myeloid leukemia was conceptual as much as clinical: the disease made it possible to molecularly understand what was driving malignant growth. His training in Owen Witte’s laboratory at UCLA, after the cloning of the BCR-ABL translocation, led him into kinase signaling and then into the era of Gleevec, when targeted therapy first showed that a malignancy could be controlled by blocking a specific molecular abnormality.
Resistance quickly became the next scientific challenge. Sequencing samples from patients responding to therapy and then relapsing revealed kinase domain mutations as a major mechanism of acquired resistance, a finding that helped open the path to next-generation drugs. The clinical consequence was profound: CML moved from a fatal disease to one in which patients now have a normal lifespan. For Sawyers, that success changed the next question rather than ending the inquiry. If resistance could be dissected in leukemia, another disease defined by treatment escape might reveal a similar opportunity. Prostate cancer, with its hormone resistance biology, became the next target.
The arc is recognizable to every oncologist who has watched a tumor adapt under therapeutic pressure. A cancer cell does not merely survive; it evolves around the bottleneck.
Why Prostate Cancer Required a Different Genomic Strategy
Chinnaiyan’s route ran through pathology, bioinformatics, and the early era of cancer genomics. He completed his scientific and medical training at the University of Michigan, then moved into a formative graduate experience in Vishva Dixit’s laboratory, where he helped define components of programmed cell death, including FADD, FLICE, and the death receptors DR3 and DR4. Those studies shaped a way of thinking about signaling networks as structured biological systems rather than isolated markers.
When he returned to clinical training and pathology, he was given an unusual opportunity to establish his own laboratory during residency. That setting proved essential. He and colleagues were working before next-generation sequencing had become routine, when cDNA microarrays were the most powerful broad-scale tool available. Chinnaiyan also helped establish Oncomine, a cancer microarray database analysis platform that made it possible to compare gene-expression patterns across tumor types and search for outlier genes in subsets of patients.
In prostate cancer specimens, that strategy revealed striking outlier expression of ETS transcription factors. The finding did not immediately answer the question of why those genes were so highly expressed. Instead, it redirected the lab toward the underlying genomic mechanism. Scott Tomlins led the follow-up work using 5′ RACE technology, which uncovered recurrent TMPRSS2-ETS gene fusions, including TMPRSS2-ERG, in a large fraction of patients with prostate cancer.
This was a sharp break from older assumptions. Recurrent fusions had been viewed mainly as lesions of hematologic malignancy, with CML as the archetype. Prostate cancer showed that common epithelial tumors could also be organized around recurrent structural alterations. The clinical meaning was immediate: prostate cancer was not just a histologic diagnosis but a molecularly diverse disease with definable drivers in at least a subset of tumors.
Precision Oncology Grew From Patient Samples, Not Abstract Theory
Sawyers emphasized that translational progress rests on basic science done over decades, not on abbreviated summaries of it. His point was practical. Young physician-scientists need more than a literature overview; they need direct experience with the experimental logic that generates the literature in the first place. In his telling, one of the reasons the prostate cancer story was so compelling is that the field did not start with a fixed hypothesis about translocations. It began with an observation: certain genes were dramatically overexpressed. The biology pointed to an answer only after the right tools were applied.
Chinnaiyan’s account reached the same conclusion from a different angle. Access to carefully annotated specimens, an NCI SPORE environment, and a willingness to let unbiased data lead the way all mattered. The discovery pipeline ran from microarray profiling to outlier analysis to fusion characterization, with each step dependent on the one before it. The result was not just a new molecular label for prostate cancer. It was a new framework for how to look at solid tumors.
The bedside implication is straightforward. Molecular pathology can expose subgroups that routine morphology cannot distinguish. In prostate cancer, that distinction opened the door to precision therapies and to a more exact understanding of diagnosis and treatment worldwide.
The Translational Problem Is Still Resistance
Even in an award focused on discovery, resistance remained the central unresolved theme. Sawyers’ experience with CML showed how quickly a targeted therapy can reshape care and how quickly malignant cells can respond in turn. His move into prostate cancer followed the same conceptual thread: identify the driver, understand escape, then design the next intervention.
That pattern matters because it frames cancer therapy as an adaptive contest. Targeted treatment can be highly effective, but the biology of resistance ensures that durable benefit depends on continued mechanistic inquiry. In CML, kinase domain mutations led to next-generation drugs. In prostate cancer, hormone resistance demanded a comparable level of molecular clarity. The research legacy honored by the Harrington Prize sits precisely in that space between discovery and recurrence, where a therapy succeeds only until the tumor learns a new route around it.
A Prize That Reflects a Field Built on Mechanism
ASCI’s selection of Chinnaiyan and Sawyers recognizes two scientists who helped establish that cancer genomics could change care when paired with disciplined biology and close attention to patient material. One built a path from leukemia translocations to targeted therapy and resistance mechanisms. The other used genomic profiling and data-driven analysis to uncover recurrent fusions in prostate cancer, a finding that altered the assumptions of solid-tumor biology.
The interview closed on the same note that shaped both careers: the most useful discoveries often begin with a question that does not fit the prevailing model. In this case, the question was not whether prostate cancer was biologically complex. It was why the data were saying something unexpected, and what treatment science should do next when they did.